SC
CAMP icon

SummitTX Capital’s CAMP4 Therapeutics CAMP Stock Holding History

SummitTX Capital’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.17M Buy
725,160
+385,639
+114% +$1.66M 0.08% 257
2026
Q1 		$1.5M Buy
+339,521
New +$1.61M 0.05% 361

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SummitTX Capital's CAMP Position: Q2 2026 in Review

SummitTX Capital increased its CAMP4 Therapeutics (CAMP) stake by 114% in Q2 2026, buying an estimated $1.66M and bringing the position to 725,160 shares worth $3.17M. The position accounts for 0.08% of the portfolio, ranked #257.

SummitTX Capital first reported a position in CAMP in Q1 2026 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • SummitTX Capital held 725,160 shares of CAMP4 Therapeutics worth $3.17M as of Q2 2026.
  • SummitTX Capital bought 385,639 CAMP4 Therapeutics shares in Q2 2026, an estimated $1.66M.
  • CAMP4 Therapeutics made up 0.08% of SummitTX Capital's portfolio in Q2 2026, its #257 holding.
  • SummitTX Capital first reported a position in CAMP4 Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.